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ABSTRACT Hemophilia A is caused by defects in the
factor VIII gene. This results in life-threatening hemorrhages
and severe arthropathies. Today, hemophiliacs are treated
with human blood-derived factor VIII. In the future, it may be
possible to use gene therapy to avoid long-term complications
of conventional therapy and to improve the quality of life.
However, initial gene therapy models using retroviral vectors
and nonviral gene transfer tcnques to introduce factor VIII
gene constructs have been hampered by low expression levels
of factor VIII. We show here that high expression levels of the
B-domain-deleted human factor VIII in primar mouse fibro-
blasts and myoblasts are obtained by using receptor-m ted,
adenovirus-augmented gene delivery (transferrinfection). We
demonstrate that, presumably owing to the high molecular
weight of factor VIII or its metabolic instability, secretion into
the blood and attainment of therapeutic in vvo levels of factor
VIII is achieved only if trnected autologous primary fibro-
blasts or myoblasts are delivered to the liver or spleen, but not
if myoblasts are implanted into muscle, a strategy known to be
successful for factor IX delivery.
In hemophilia A there is a genetic defect of the coagulation
factor VIII, a trace plasma glycoprotein, which acts as a
cofactor for factor IX in the activation of factor X (reviewed
in refs. 1 and 2). The factor VIII gene encodes a protein of
2351 amino acids containing six domains (3-5). The central,
B domain of 980 amino acids, to which high-mannose oligo-
saccharides are added in the endoplasmic reticulum, is dis-
carded during proteolytic activation of factor VIII (1, 3, 5).
The B-domain-deleted form of the factor VIII gene has been
chosen for use in gene transfer experiments with recombinant
retrovirus because (i) the retroviral vectors do not readily
accommodate the full-length cDNA (8.8 kb) and (ii) the
B-domain-deleted protein is more easily processed in trans-
duced cells than the full-length protein (6-9). However, the
expression of factor VIII obtained with these retroviral
vectors was too low for in vivo generation of detectable
plasma levels of factor VIII (10). The insufficient synthesis
rates after retrovirus-mediated transduction have been ex-
plained, at least in part, by the observation that sequences of
the factor VIII gene interfere with its own transcription,
resulting in low titers of the retroviral vectors and in low
factor VIII production rates in the transduced cells (ref. 11
and R. C. Hoeben, personal communication). With "trans-
ferrinfection," neither the problem of interference of factor
VIII sequences with vector production nor such size restric-
tion for the delivery of DNA molecules exists, because the
gene, highly condensed by polylysine-modified transferrin, is
carried on the surface of the adenovirus (refs. 12-15 and
unpublished results). Moreover, transferrinfection has been
shown to introduce %20 copies of genes into cells, which
correlates with high expression rates. To make our data
directly comparable with published work, we have used the
truncated version ofthe factor VIII gene in the present study.
Our aim is to test whether the specific technical features of
transferrinfection permit increased factor VIII expression in
various cell types. Moreover, it is necessary to define the in
vitro expression level of factor VIII which is required for
future gene therapy protocols for hemophilia A. We demon-
strate here that the factor VIII expression rates of transferr-
infected cells exceed the values which have been obtained
with other gene transfer techniques by a factor of 10-100 and
that production rates of 1000 milliunits per 106 cells in 24 hr
are sufficient to generate therapeutic plasma levels in mice
after implantation ofex vivo transfected cells. Comparison of
various cell implantation strategies reveals that direct secre-
tion of the factor VIII into the blood is a prerequisite for
successful in vivo production.
MATERIAL AND METHODS
Isolation ofPrimary Cells. Primary cells were isolated from
the hindlimb muscles of 4-week-old C3H/He mice by re-
peated digestions ofminced muscle tissue with 0.25% trypsin
and 0.1% collagenase in phosphate-buffered saline (PBS)
containing 0.1% bovine serum albumin (BSA), at 370C. The
enzymatically released cells were mixed with an equal vol-
ume of Dulbecco's modified Eagle's medium (DMEM) plus
200% fetal bovine serum, filtered, and centrifuged at 500 x g
for 15 min. The cells were then resuspended in DMEM plus
20% fetal bovine serum and plated onto 10-cm culture dishes.
After 60 min the nonadherent cells were found to be greatly
enriched for myoblasts, whereas the adherent cells were
predominantly fibroblasts; the myoblast-enriched, nonadher-
ent fraction was seeded onto laminin-coated dishes.
Generation of the Factor VIII Gene Construct. The full-
length factor VIII construct pF8CISa (16), a gift from Gen-
entech, was digested with Cel II. The resultant 5648-bp Cel
II fragment containing the B domain was replaced by a
2990-bp Cel II fragment isolated from the B-domain-deleted
clone pUC/F8-dB2.6 (deletion from amino acid 746 to amino
acid 1638), which was obtained from R. C. Hoeben (7). The
2990-bp fragment was ligated into pF8CISa so that the
resulting expression vector pF8-dB2.6 was identical to the
full-length F8 construct except for the B-domain deletion.
The expression vector contained a cytomegalovirus promot-
er/enhancer followed by a synthetic intron and the B-do-
main-deleted factor VIII cDNA; 3' of the cDNA there was a
simian virus 40 poly(A)-addition sequence. The vector in-
Abbreviation: BSA, bovine serum albumin.
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cluded also a (3-lactamase gene, a prokaryotic origin of
replication, and a dihydrofolate reductase gene.
Tranfection of Cels. Cells (5 x 10W) were transferrinfected
with 2-12 x 109 particles of the biotinylated human ElA-
defective adenovirus type 5 (d1312) which had been modified
with 600 ng of streptavidin-polylysine and complexed to 6 pg
of factor VIII expression plasmid. Then 6.8 pg of transferrin-
polylysine was added (14). The resulting complexes were
mixed with 1.5 ml of DMEM containing 2% fetal bovine
serum, incubated with the cells for 4 hr, and then removed
and replaced by 2 ml ofDMEM containing 10% fetal bovine
serum.
Immuofluorescence Microscopy. Transferrinfected C2C12
myoblasts were fixed with acetone:methanol (1:1) at -20'C
for 10 min, washed with PBS, and incubated for 30 min at
room temperature with an antibody directed against the
human factor VIII:c antigen (ESH 4, American Diagnostica,
Greenwich, CT) diluted 1:10 in PBS. After the cells were
washed with PBS, a Texas Red-conjugated anti-mouse im-
munoglobulin antibody (EY Laboratories) diluted 1:20 in
PBS was applied for 30 min to the cells. Thereafter the cells
were washed three times with PBS, rinsed briefly in water
and in 96% ethanol, and mounted with Moviol.
In Vivo Production of Factor VIII. Primary mouse fibro-
blasts (from the first passage) and C2C12 myoblasts were
transferrinfected with the B-domain-deleted factor VIII con-
struct as described above. Six hours after transfection the
cells were trypsinized, washed, and suspended at 1 x 106
cells per 100 A4 of Earle's buffered salt solution (1 unit of
heparin was added to the preparation for mice 5 and 6). After
laparotomy, 1 x 106 cells were injected into the spleens of six
female C3H/He mice (4 weeks old) that had been anesthe-
tized with Avertin. The injection sites were then ligated and
the abdominal wounds were closed. Alternatively, 1 x 106
C2C12 myoblasts were implanted into the musculus quadri-
ceps femuris essentially as described (17). Blood was col-
lected by cardiac puncture 24 hr later and factor VIII con-
centrations were determined with a sandwich ELISA specific
for human factor VIII. For negative control, plasma from
mice which had received implantations ofprimary fibroblasts
transferrinfected with a luciferase reporter gene were ana-
lyzed in parallel.
Analysis of Factor VIII Production. In the in vitro experi-
ments the factor VIII activity that was released into the
medium within 24 hr was measured with a chromogenic
substrate assay (Coatest; KabiVitrum, Molndal, Sweden).
For measurement of in vivo produced human factor VIII an
ELISA which does not react with murine factor VIII has been
established. The ELISA is based on two monoclonal anti-
bodies directed against human factor VIII (ESH 4 and ESH
8; American Diagnostica). ESH 4 (25 jg/ml in 0.1 M
NaHCO3/0.5 M NaCl, pH 9.0) was coupled to the ELISA
plates overnight at 4°C, washed with 0.1% Tween 20 in PBS,
and blocked with 1% BSA in PBS. The samples were applied
in 0.05 M Tris HCl/1 M NaCl/2% BSA, pH 7.5, over 4 hr at
room temperature, the plates were washed, and ESH 8 (2.5
pg/ml in 0.05 M Tris-HCl/1 M NaCl/2% BSA, pH 7.5) that
had been biotinylated with N-hydroxysuccinimidobiotin
(Pierce) was added for 2 hr at room temperature. The color
reaction was performed with peroxidase-conjugated strepta-
vidin (Boehringer Mannheim) and o-phenylenediamine dihy-
drochloride as substrate. For all factor VIII measurements,
the international human factor VIII:c standard (from the
National Institute for Biological Standards and Control,
Hertfordshire, U.K.) and normal mouse plasma were used as
references.
RESULTS
In Vitro Production of Factor VIII in Primary Cells and Cell
Lines. Primary myoblasts and primary fibroblasts transferr-
infected with the B-domain-deleted factor VIII produced
between 620 and 1250 milliunits offactor VIII within 24 hrper
106 cells (Table 1), which exceeded by a factor of 10-100 the
values reached by retroviral transduction or nonviral gene
transfer techniques (6-9, 11, 18, 19). Surprisingly, primary
fibroblasts were even more active in producing the B-domain-
deleted factor VIII than the 3T3 fibroblast cell line, although
the cell line expressed a luciferase reporter gene driven by an
identical cytomegalovirus promoter/enhancer, which served
as an indicator for the transfection efficiency, at higher levels
than the primary cells (Table 1). This suggests that primary
cells are more suited for the production of active B-domain-
deleted factor VIII than established cell lines, perhaps be-
cause they support transcription or the posttranslational
maturation steps in a more efficient manner than correspond-
ing cell lines.
Long-Term Factor VIII Production in Muscle Cells. Trans-
ferrinfected genes are expressed transiently in proliferating
cells, but expression is protracted in growth-arrested cells
almost to the lifespan of the cells in vitro (14, 15). To test
whether factor VIII can be expressed for prolonged periods
in muscle cells, C2C12 murine myoblasts were transferrin-
fected with the B-domain-deleted human factor VIII gene and
were treated with horse serum to induce differentiation of
myoblasts into nondividing myotubes. The initial factor VIII
production per 24 hr was in the range of 4000 milliunits per
106 cells (Fig. 1). After the differentiation stimulus, which led
to formation of myotubes from about two-thirds of the
myoblasts, factor VIII production remained at high levels, in
the range of 1000 milliunits per 106 cells per 24 hr for the first
3 weeks of culture and then after 35 days declined to w50
milliunits per 24 hr. The factor VIII values at the end of the
observation period do not take into account that a consider-
able fraction of the cells (in transfected dishes as well as in
nontransfected controls) had already died, whereas the cal-
culation of the factor VIII activities was normalized to the
cell number at the beginning of the experiment.
Factor VIII Production in Myoblasts and Myotubes. Immu-
nofluorescence microscopy revealed a positive factor VIII
reaction in up to 40%o of the C2C12 myoblasts transferrin-
fected with the truncated factor VIII gene construct (Fig.
2A). However, there were fewer cells positive for factor VIII
as compared to the number of (-galactosidase-positive cells
seen in myoblasts transferrinfected in parallel with a 3-ga-
lactosidase reporter gene as an independent indicator of the
transfection efficiency (data not shown). After induction of
differentiation, myotubes reactive for factor VIII (Fig. 2B)
were observed, which indicates that neither the transfernin-
Table 1. Capacity of various primary cells and cell lines for
production of B-domain-deleted human factor VIII
Human factor VIII, ifliunits Luciferase
per 106 cells in 24 hr activity, lightCell - units per 103
type Exp. 1 Exp. 2 cells
pFB 800±44 1247 ± 220 2,923 255
3T3 448 ± 36 612 ± 36 18,364 536
pMB 616 79 1164 ± 36 3,860 697
C2C12 735 + 89 827 ± 42 9,545 ± 761
Primary mouse fibroblasts (pFB) and myoblasts (pMB) as well as
the fibroblast cellline NIH 3T3 andthe myoblast cell line C2C12 were
transferrinfected in two independent series of experiments (Exp. 1
and Exp. 2) in triplicates. The indicated factor VIII activities
represent mean values of each of the series with the standard
deviations indicated. An international factor VII:c standard served
as reference. For negative control of the factor VIII assay, and a
parameter for the transfection efficiency, cells were transferrinfected
in parallel to the Exp 2 series with a cytomegalovirus-driven lu-
ciferase reporter gene instead of the factor VIII construct.
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FIG. 1. Long-term expression offactor VIII. C2C12 myoblasts (5
x 105) were transferrinfected with the B-domain-deleted human
factor VIII and induced to differentiate into myotubes 48 hr after
transfection by incubation for 5 days in DMEM containing 2% horse
serum. Factor VIm production per 24 hr was measured (Coatest;
KabiVitrum) at the indicated time points after transfection. The
factor VIII activities represent mean values of three parallel trans-
fections with the standard deviations indicated by bars.
fection nor the high-level production offactor VIII prevented
myoblast differentiation.
Short-Term Generation of Therapeutic Factor VIII Plasma
Levels in Mice. Primary fibroblasts were transferrinfected
with the B-domain-deleted factor VIII gene construct and
implanted into the spleens of syngeneic mice. For detection
of the in vivo produced human factor VIII in normal mice, an
ELISA specific for human factor VIII has been developed.
All animals implanted with 1 x 106 cells had factor VIII
plasma levels ranging from 8.5 to 17.4 ng/ml (mean value,
13.7 ng/ml) at 24 hr after cell transfer (Fig. 3), which clearly
exceeded the 5-ng/ml limit anticipated as necessary for a
therapeutic effect (normal factor VIII concentration in the
plasma is between 50 and 200 ng/ml) (2). However, only
negligible levels of factor VIII were found at 48 hr. The
reason for this rapid turn-off is not known. As revealed by
implantation of primary fibroblasts transferrinfected with a
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FIG. 3. In vivo production of factor VIII after implantation of
transferrinfected cells into mice. Primary fibroblasts were implanted
into the spleen ofmice after transferrinfection with B-domain-deleted
human factor VIII (mice 1-6). In parallel, transferrinfected C2C12
myoblasts were implanted into the muscle (mouse 7) or into the
spleen (mouse 8) of mice. The generated plasma concentrations of
human factor VIm were measured with an ELISA that is specific for
human factor VIII (values represent ng of factor VIII per ml of
plasma; n.d., not detectable).
luciferase reporter gene into the spleen, the cells settled in the
spleen and liver, but no luciferase activity was found in lung,
kidney, ovary, or testis (data not shown). In an alternative
approach, transferrinfected C2C12 myoblasts, which pro-
duced in vitro amounts of factor VIII similar to those pro-
duced by primary fibroblasts (see Table 1), were implanted
into the musculus quadriceps femuris of mice. In this case,
however, the animals did not generate detectable plasma
levels of factor VIII. To demonstrate that the absence of
human factor VIII in the circulation was not due to insuffi-
cient in vivo production of factor VIII by myoblasts, trans-
ferrinfected C2C12 myoblasts were implanted into the spleen
of a control mouse. This animal revealed similar factor VIII
plasma levels as had been obtained with transferrinfected
fibroblasts.
DISCUSSION
The development ofgene therapy for hemophilia A is depen-
dent on a gene delivery system which guarantees high pri-
FIG. 2. Immunohistochemical detection of factor VIII in transferrinfected C2C12 myoblasts and myotubes. (A) C2C12 myoblasts
transferrinfected with the B-domain-deleted human factor VUI. (B) Transferrinfected C2C12 myoblasts were induced to differentiate into
myotubes after gene delivery. (C) Negative control with C2C12 myoblasts transferrinfected with a cytomegalovirus promoter/p-galactosidase
reporter gene construct. The immunofluorescence reactions were performed on C2C12 myoblasts (A and C) 48 hr after transfection and after
induction of differentiation into myotubes (B) at day 7 after transfection. (x250.)
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mary transfection efficiencies and does not require selection
for transfected cells, since for this therapy primary patient
cells are the target for genetic modification. Therefore the
strategies (i.e., selection for stable expression and amplifi-
cation of the inserted gene) which have been previously used
to increase factor VIII expression in transfected cell lines for
in vitro production of recombinant factor VIII are not appli-
cable for gene therapy (20). Transferrinfection is character-
ized by its high transfection efficiency, with detectable gene
expression in 30% to almost 100% of the transfected cells.
Moreover, transferrinfection introduces multiple copies of
the gene into the target cells, which leads to very high
expression rates. Israel and Kaufman (19) have demonstrated
in stably transfected cells that there is a correlation between
the number of amplified copies of the factor VIII gene
construct and the amount of secreted factor VIII.
The cell types which normally secrete factor VIII have not
been definitely identified, but liver transplantation rectifies
hemophilia A and factor VIII mRNA is detectable in the liver
and in isolated hepatocytes, which suggests that liver cells
are a primary site for factor VIII synthesis (21-24). For gene
therapy of hemophilia A, it may be possible to implant
genetically modified cells other than hepatocytes. Primary
fibroblasts and myoblasts are interesting target cells for
ectopic expression of factor VIII, since these cells can be
easily isolated from patients and allow high transfection
efficiencies in vitro. There are many groups which have
demonstrated secretion of proteins into the blood from ex
vivo transfected cells after implantation into various sites
(reviewed in ref. 25). For instance, transfected myoblasts can
be implanted into the muscle of mice, which leads to cell
fusion between the myoblasts and preexisting muscle fibers.
This is a very promising approach, since upon fusion of the
myoblasts with the muscle fibers the genetic information is
transferred into the muscle fiber, thus generating long-lived
genetically modified cells. An alternative technique for in
vivo production of recombinant proteins is to implant trans-
fected fibroblasts into the subcutis or into the peritoneum.
However, Hoeben et al. (10) reported that subcutaneous
implantation of 5 x 106 fibroblasts that were retrovirally
transduced with a B-domain-deleted factor VIII and encap-
sulated in a collagen matrix generated no detectable plasma
levels of factor VIII. In contrast to this finding with factor
VIII, it was reported that factor IX was released into the
circulation from myoblasts that had been implanted into the
muscle (17, 26, 27). We found that intramuscular implantation
of myoblasts producing high amounts of factor VIII in vitro
resulted in no detectable blood levels (Fig. 3, animal 7),
whereas implantation of myoblasts or fibroblasts into the
spleen and liver generated plasma levels which clearly ex-
ceeded the limit required for therapy. One possible explana-
tion for these discrepancies is that factor VIII is a much larger
molecule than factor IX, and, therefore, diffusion from the
muscle or subcutaneous implantation site into blood or lymph
capillaries is restricted. Moreover, rapid association of newly
synthesized factor VIII with von Willebrand factor in the
blood is required for stabilization of factor VIII (1). The
implantation of factor VIII-producing cells at a site where
direct secretion of factor VIII into the blood is possible, as is
the case in the liver or spleen, appeared to be essential.
These data demonstrate the high capacity of transferrin-
fection for the delivery of truncated factor VIII gene con-
structs into primary cells. The expression, which was ob-
tained without selection for transfected cells and/or ampli-
fication of the introduced factor VIII gene construct, was
sufficient for the generation of therapeutic blood levels in
mice. For application of this gene transfer technique in gene
therapy of hemophilia A, further developments in the field of
cell transplantation technology are required so that long-term
survival of ex vivo modified cells can be achieved. Moreover,
improvements in the factor VIII vector design are expected
to further increase factor VIII production in transfected cells
(11).
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